Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer

Fleming, Patrick; Karpio, Sylvia; Lombardo, N.J.

doi:10.6004/jadpro.2021.12.7.8

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus far, SG underwent clinical development in different tumor types, showing a remarkable efficacy in the treatment of advanced triple-negative breast cancer (TNBC). In April 2021, the drug received Food and Drug Administration (FDA) approval for the treatment of metastatic TNBC patients who failed at least two prior lines of systemic therapy [ 21 , 22 ]. In the same month, SG was granted accelerated approval for the treatment of advanced urothelial carcinoma, and it is currently under investigation for the treatment of many other types of tumors [ 17 , 23 , 24 , 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors

et al. 2021

View full text Add to dashboard Cite

Human trophoblast cell-surface antigen-2 (Trop-2) is a membrane glycoprotein involved in cell proliferation and motility, frequently overexpressed in epithelial tumors. Thus, it represents an attractive target for anticancer therapies. Sacituzumab govitecan (SG) is a third-generation antibody-drug conjugate, consisting of an anti-Trop-2 monoclonal antibody (hRS7), a hydrolyzable linker, and a cytotoxin (SN38), which inhibits topoisomerase 1. Specific pharmacological features, such as the high antibody to payload ratio, the ultra-toxic nature of SN38, and the capacity to kill surrounding tumor cells (the bystander effect), make SG a very promising drug for cancer treatment. Indeed, unprecedented results have been observed with SG in patients with heavily pretreated advanced triple-negative breast cancer and urothelial carcinomas, and the drug has already received approval for these indications. These results are coupled with a manageable toxicity profile, with neutropenia and diarrhea as the most frequent adverse events, mainly of grades 1–2. While several trials are exploring SG activity in different tumor types and settings, potential biomarkers of response are under investigation. Among these, Trop-2 overexpression and the presence of BRCA1/2 mutations seem to be the most promising. We review the available literature concerning SG, with a focus on its toxicity spectrum and possible biomarkers of its response.

show abstract

Section: Introductionmentioning

confidence: 99%

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors

et al. 2021

View full text Add to dashboard Cite

show abstract

Current status of immunotherapy for non-small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Nowadays, lung cancer is still the deadliest oncological disease in the world. Among them, non-small cell lung cancer (NSCLC) accounts for 80%∼85% of all lung cancers, and its 5-year survival rate is less than 15%, making the situation critical. In the past decades, despite some clinical advances in conventional treatments, the overall survival rate of NSCLC is still not optimistic due to its unique physiological conditions and the frequent occurrence of tumor escape. In recent years, immunotherapy has become a new hot spot in lung cancer research, including antibody therapy and cell therapy, which have been developed and utilized one after another, especially immune checkpoint inhibitor (ICI). These approaches have effectively improved the overall survival rate and objective response rate of NSCLC patients by enhancing the immune capacity of the body and targeting tumor cells more effectively, which is more specific and less toxic compared with conventional chemotherapy, and providing more strategies for NSCLC treatment. In this paper, we reviewed the relevant targets, clinical progress and adverse reaction in monoclonal antibodies, antibody-drug conjugates, ICI, bispecific antibodies, T-cell receptor engineered T cell therapy (TCR-T), Chimeric antigen receptor T-cell immunotherapy (CAR-T), and also report on their combination therapy from the immune-related background to provide better NSCLC treatment and prospective.

show abstract

Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer

Cited by 2 publications

References 10 publications

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors

Current status of immunotherapy for non-small cell lung cancer

Contact Info

Product

Resources

About